Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1784)	3/28/2005 1:03:02 PM
From: richardred	Read Replies (1) \| Respond to of 2173

I think this is what is putting pressure on AMLN of recent. I think the insiders remembered this. Getting parody with Lilly's exercise price. For me anyway, Looks like it's time to buy and write some options. 10% percent of outstanding shares are currently short. Snip of a snip >These milestones may be convertible into Amylin equity at Lilly's option under certain circumstances. >Lilly will make initial nonrefundable payments to Amylin totaling $80 million. Lilly will also purchase $30 million of Amylin common stock at a price of $18.69 per share. In addition, in the future, Lilly will pay Amylin up to $85 million upon the achievement of certain development and product profile milestones of AC2993, including long-acting release formulations of the product candidate. These milestones may be convertible into Amylin equity at Lilly's option under certain circumstances. Lilly will also make additional future payments to Amylin of up to $130 million contingent upon global commercialization of AC2993, including long-acting release formulations of the product candidate.